VIVUS LLC announced it has entered into a strategic partnership with UpScriptHealth. The program, titled "VIVUS Engage," will establish a robust online telemedicine platform for the distribution of QSYMIA (phentermine and topiramate extended-release capsules CIV), the leading non-injectable branded weight loss medication in the U.S. for adults. Under the terms of the agreement, UpScript LLC will make QSYMIA available to patients through its proprietary Telehealth Platform.

QSYMIA is indicated as an FDA-approved adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in some adults and certain pediatric patients aged 12 years and older. Patients will be able to access high quality health care and directly communicate with a healthcare provider through the UpScript Platform. They may also select to have their medication mailed directly to them through a mail order pharmacy.

This solution is designed to increase access to QSYMIA nationwide, offer patients a time-saving solution and help them manage the coverage administration process through UpScript's benefit support capabilities. With over 20 years of experience and more than one million patients served, UpScriptHealth specializes in creating effective web-based campaigns for pharmaceutical companies. Its comprehensive services include virtual prescribing, coverage and benefit support, as well as long-term adherence support.

For patients actively seeking online support and solutions, UpScriptHealth offers a fast and convenient option. The projected global impact of obesity is staggering, with an estimated one billion people expected to be affected by 2030. This marks nearly a twofold increase from the 2020 prevalence of around 511 million.

Significantly, obesity escalates the risk of type 2 diabetes, hypertension, and dyslipidemia. Consequently, this increased risk contributes to an overall increased susceptibility to cardiovascular disease and mortality. Achieving and maintaining healthy weight goals can play a crucial role in mitigating this risk.

QSYMIA was approved by the U.S. Food and Drug Administration in 2012 for chronic weight management. The once-daily pill is covered by the majority (81%) of commercial healthcare plans and is indicated for long-term use. QSYMIA is designed to help patients manage hunger and reduce cravings throughout the day.

Combined with a healthy diet and exercise, it has been proven to help patients lose weight and maintain weight loss.